Comparative Pharmacology
Head-to-head clinical analysis: TIMENTIN IN PLASTIC CONTAINER versus TINDAMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIMENTIN IN PLASTIC CONTAINER versus TINDAMAX.
TIMENTIN IN PLASTIC CONTAINER vs TINDAMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Timentin is a combination of ticarcillin, a penicillin-class beta-lactam antibiotic, and clavulanate, a beta-lactamase inhibitor. Ticarcillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while clavulanate irreversibly inhibits beta-lactamases, preventing degradation of ticarcillin.
Tindamax (tinidazole) is a nitroimidazole antibiotic that enters bacterial and protozoal cells, where the nitro group is reduced by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It exhibits activity against anaerobic bacteria and protozoa.
3.1 g (ticarcillin 3 g + clavulanate 0.1 g) IV every 4 to 6 hours; maximum 18 g per day.
100 mg intravenously every 8 hours over 60 minutes.
None Documented
None Documented
Ticarcillin: ~1.2 hours; Clavulanate: ~1.0 hours. Prolonged in renal impairment (ticarcillin up to 15 hours in ESRD).
Terminal elimination half-life is 4-6 hours; prolonged to 10-12 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~70-80% of ticarcillin and ~60-70% of clavulanate excreted unchanged in urine within 6 hours. Biliary/fecal: Minor (<5%).
Primarily renal excretion (70-80% as unchanged drug) with 10-15% fecal elimination via biliary secretion.
Category C
Category C
Antibiotic
Antibiotic